Deja Vu: Second Probe Finds Manipulated Trial Data for Novartis AG Drug
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
The scandal over research into the Diovan heart drug in Japan is beginning to resemble a game of Whack-A-Mole. One day after Novartis attempted to put the matter to rest by announcing its own investigation was completed, another university has disclosed that data in a trial was manipulated and the first author of the study, a professor at the university, says the work will be retracted. In a press conference, Kazuhiro Hashimoto, who chairs an investigation committee at the Jikei University School of Medicine, indicated that a former Novartis employee might have manipulated the data, while noting that the former worker denied wrongdoing in an interview, according to The Japan Times.
Help employers find you! Check out all the jobs and post your resume.
The scandal over research into the Diovan heart drug in Japan is beginning to resemble a game of Whack-A-Mole. One day after Novartis attempted to put the matter to rest by announcing its own investigation was completed, another university has disclosed that data in a trial was manipulated and the first author of the study, a professor at the university, says the work will be retracted. In a press conference, Kazuhiro Hashimoto, who chairs an investigation committee at the Jikei University School of Medicine, indicated that a former Novartis employee might have manipulated the data, while noting that the former worker denied wrongdoing in an interview, according to The Japan Times.
Help employers find you! Check out all the jobs and post your resume.